drugset / Trial / NCT00152685
High Dose Hyperoncotic Serum Albumin for the Treatment of the Acute Phase of Severe Head Injury
RandomizedSingle-groupSingle-blind
Summary
Experimentally high dose of hyperoncotic human serum albumin improve neurological recovery after head injury reduce cerebral edema and normalize apparent diffusion coefficient of water after ischemia reperfusion. The main hypothesis is that early administration of hyperoncotic serum albumin is able to reduce intracranial pressure for several days after severe head injury and thus reduce mortality and morbidity.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Human serum albumin | Protein / enzyme biologic | — | — |